The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer

Basic and Clinical Pharmacology and Toxicology

Volumn 116, Issue 1, 2015, Pages 19-24

  Iversen, Trine Zeeberg ^a   Andersen, Mads Hald ^a   Svane, Inge Marie ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; DABRAFENIB; IMIQUIMOD; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 2; IPILIMUMAB; MONTANIDE ISA 51; NIVOLUMAB; PEPTIDE VACCINE; SARGRAMOSTIM; SURVIVIN; TEMOZOLOMIDE; VEMURAFENIB; ALPHA INTERFERON; ALPHA2A INTERFERON; DACARBAZINE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; SIPULEUCEL T; TISSUE EXTRACT;

ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DRUG MEGADOSE; HUMAN; LIVER METASTASIS; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; MELANOMA; METASTATIC MELANOMA; METRONOMIC DRUG ADMINISTRATION; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; REGULATORY T LYMPHOCYTE; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SHORT SURVEY; SIDE EFFECT; TREATMENT RESPONSE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; METABOLISM; PROCEDURES; PROSTATIC NEOPLASMS;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; DACARBAZINE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-ALPHA; INTERLEUKIN-2; LUNG NEOPLASMS; MALE; MELANOMA; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; TISSUE EXTRACTS;

EID: 84919845152     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12320     Document Type: Short Survey

References (41)

1. Curtin Ja, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47.
2. Curtin JA, Stark MS, Pinkel D, Hayward NK, Bastian BC. PI3-kinase subunits are infrequent somatic targets in melanoma. J Invest Dermatol 2006;126:1660-3.
3. Forsea AM, Del Marmol V, de Vries E, Bailey EE, Geller AC. Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol 2012;167:1124-30.
4. Frøslev T, Grann AF, Olsen M, Olesen AB, Schmidt H, Friis S et al. Completeness of TNM cancer staging for melanoma in the Danish Cancer Registry, 2004-2009. Clin Epidemiol 2012;4(Suppl 2):5-10.
5. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.
6. Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013;24:2174-80.
7. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66.
8. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
9. Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-65.
10. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
11. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
12. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
13. Romero P. Current state of vaccine therapies in non-small-cell lung cancer. Clin Lung Cancer 2008;9(Suppl 1):S28-36.
14. Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009;10:371-4.
15. Brahmer JR. Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol 2013;31:1021-8.
16. Brahmer JR. Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? Semin Oncol 2014;41:126-32.
17. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
18. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005;117:294-9.
19. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94.
20. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012;482:405-9.
21. Hallmarks of Cancer: The next generation. http://download.cell.com/pdf/PIIS0092867411001279.pdf?intermediate=true(last accessed on 26 March 2014).
22. Munn DH, Mellor AL. Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007;117:1147-54.
23. Sørensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TNM et al. The immune system strikes back: cellular immune responses against indoleamine 2, 3-dioxygenase. PLoS One 2009;4:e6910.
24. Sørensen RB, Hadrup SR, Svane IM, Hjortsø MC, Thor Straten P, Andersen MH. Indoleamine 2, 3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 2011;117:2200-10.
25. Iversen TZ. Immune modulations during chemoimmunotherapy & novel vaccine strategies-in metastatic melanoma and non small-cell lung cancer. Dan Med J 2013;60:B4774.
26. Iversen TZ, Brimnes MK, Nikolajsen K, Andersen RS, Hadrup SR, Andersen MH et al. Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients. Oncoimmunology 2013;2:e23288.
27. Keilholz U, Scheibenbogen C, Tilgen W, Bergmann L, Weidmann E, Seither E et al. Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer 1993;72:607-14.
28. Andersen MH, Gehl J, Reker S, Pedersen LØ, Becker JC, Geertsen P et al. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 2003;13:449-59.
29. Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J et al. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2, 3 dioxygenase. Clin Cancer Res 2014;20:221-32.
30. Ku GY, Yuan J, Page DB, Schroeder SEA, Panageas KS, Carvajal RD et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010;116:1767-75.
31. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001;19:3477-82.
32. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
33. Schilling B, Sondermann W, Zhao F, Griewank KG, Livingstone E, Sucker A et al. Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol 2014;25:747-53.
34. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012;11:215-33.
35. Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 2009;58:1627-34.
36. Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004;22:610-6.
37. Mitchell DA, Cui X, Schmittling RJ, Sanchez-Perez L, Snyder DJ, Congdon KL et al. Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 2011;118:3003-12.
38. Sampson JH, Schmittling RJ, Archer GE, Congdon KL, Nair SK, Reap EA et al. A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One 2012;7:e31046.
39. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
40. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.
41. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-49.